Citadel Advisors’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Citadel Advisors’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-498	Closed	-$16K	–	15932
2022 Q4	$16K	Buy	+498	New	+$19.7K	﹤0.01%	13295
2022 Q3	–	Sell	-5,371	Closed	-$246K	–	14004
2022 Q2	$226K	Buy	5,371 +2,219	+70%	+$103K	﹤0.01%	10451
2022 Q1	$214K	Buy	3,152 +263	+9%	+$21.9K	﹤0.01%	11366
2021 Q4	$351K	Buy	+2,889	New	+$488K	﹤0.01%	10564
2021 Q3	–	Sell	-974	Closed	-$193K	–	14973
2021 Q2	$268K	Sell	974 -811	-45%	-$205K	﹤0.01%	11540
2021 Q1	$382K	Buy	1,785 +652	+58%	+$180K	﹤0.01%	10298
2020 Q4	$274K	Buy	+1,133	New	+$140K	﹤0.01%	9226
2020 Q2	–	Sell	-511	Closed	-$38K	–	10711
2020 Q1	$38K	Buy	+511	New	+$48.7K	﹤0.01%	9131

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's EVLO Position: Q1 2023 in Review

Citadel Advisors sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 498 shares — an estimated $16K sold.

Citadel Advisors first reported a position in EVLO in Q1 2020 and held it in 8 quarters. The position peaked at $382K in Q1 2021. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

Citadel Advisors reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 498 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $16K.
Citadel Advisors first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
Citadel Advisors's Evelo Biosciences, Inc. Common Stock position peaked at $382K in Q1 2021.
39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.